Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hecogenin is a naturally occurring steroidal sapogenin primarily extracted from plants of the *Agave* genus, such as *Agave sisalana*. It is a significant industrial precursor used in the semi-synthesis of various steroid hormones, including corticosteroids. Beyond its role as a chemical intermediate, hecogenin has been investigated for its bioactive properties, particularly in the context of inflammatory and proliferative diseases. Research indicates that hecogenin can induce apoptosis in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) by activating the p38 mitogen-activated protein kinase (MAPK) signaling pathway. This pro-apoptotic activity is associated with the upregulation of cyclooxygenase-2 (COX-2) expression and an increase in endogenous prostaglandin E2 (PGE2) production, highlighting its potential as a therapeutic candidate for managing synovial hyperplasia in RA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hecogenin.